The Daily Ledger

HealthNews

ICMR Turns a Century of Health Research Innovations Into Industry Partnerships

The Indian Council of Medical Research says it has completed 100 technology-transfer deals in under two years. At its November research summit, it exchanged 20 licensing agreements covering eight technologies with nine Indian companies and unveiled new research, surveillance and training initiatives.

The Daily Ledger Staff · Updated 4 min read
Editorial illustration showing biomedical researchers developing diagnostic and medical technologies, with visual links from a research laboratory to a clinic and healthcare manufacturing
Illustration generated with AI

The Indian Council of Medical Research (ICMR) has reached 100 successful technology-transfer deals, marking a milestone in efforts to move publicly supported biomedical research towards practical use. The council announced the achievement at the third Department of Health Research–ICMR Health Research Excellence Summit, held at Bharat Mandapam in New Delhi on November 16 and 17.

At a technology-transfer ceremony during the summit, ICMR exchanged 20 licensing agreements covering eight technologies with nine Indian companies. The agreements brought the cumulative number of successful transfers to 100 in less than two years after the launch of its Medical Innovations Patent Mitra initiative in March 2025.

From laboratory research to wider use

Technology transfer is the process through which research institutions make an invention, process or technical method available to another organisation for development, production or use. In health research, this can help bridge the gap between a promising laboratory result and a product or service that can be manufactured, adopted by healthcare providers or made available to the public.

ICMR said the summit's innovation exhibition showcased 17 technologies developed by its institutes and partner institutions. A separate session presented 10 technologies and eight patents. The council described the partnerships as part of a wider effort to translate indigenous research into practical applications through collaboration with industry.

The announcement did not identify every licensed technology or disclose the commercial terms of the agreements. The number of transfers is therefore a measure of licensing and partnership activity, rather than evidence that all 100 innovations are already widely available in hospitals or the market.

New initiatives focus on research translation and surveillance

Three initiatives were launched alongside the technology-transfer milestone. The Department of Health Research's new Research to Action Vertical is intended to turn research evidence into decision-ready inputs for government policies and programmes.

A Syndromic Surveillance initiative under the Virus Research and Diagnostic Laboratories scheme is designed to create an early-warning network for disease outbreaks across 70 Virus Research and Diagnostic Laboratories and Infectious Disease Research and Diagnostic Laboratories. Such networks can help public-health authorities identify unusual patterns of symptoms and coordinate further investigation, although the announcement does not provide a launch timetable or operational performance measures.

The Dr M K Bhan Young Medical Faculty PhD Portal was also launched as a centralised source of information for prospective applicants. ICMR additionally released its Antimicrobial Resistance Annual Report and standard operating procedures, bringing together national evidence and standardised laboratory processes relating to antimicrobial resistance.

A national research network

The two-day summit brought together more than 600 scientists, researchers, innovators, administrators and policymakers from ICMR institutes, partner organisations, government bodies and academia. It also marked 115 years of ICMR's work in biomedical research. The council, established in 1911 and headquartered in New Delhi, functions under the Department of Health Research in the Ministry of Health and Family Welfare.

The summit recognised contributions across nine categories covering research publications, technologies, patents and institutional performance. It also honoured the top 100 school students selected through the SHINE National Competition. The programme is aimed at students in Grades 9 to 12 and seeks to encourage interest in public health and biomedical research.

What the milestone means for Indian health innovation

For research institutions, a licensing agreement can provide a route for a technology to move beyond academic development. For companies, access to research developed in public institutions may offer a starting point for further engineering, validation, manufacturing and distribution. The ultimate public benefit depends on whether products meet regulatory requirements, prove safe and effective where relevant, and reach the health systems or communities that need them.

The next indicators to watch will be the technologies that emerge from the agreements, their progress through validation and regulatory processes, and evidence of adoption. The new surveillance and research-to-policy initiatives will also need sustained coordination, trained personnel and reliable data to demonstrate their value.

ICMR's 100-deal milestone signals a stronger emphasis on connecting research with industry. Its significance will be judged not only by the number of agreements signed, but by the quality of the technologies and the extent to which they improve access to useful, affordable healthcare.

Sources

Written with automated tools from the sources above and published without editor review. Spotted an error? Tell us · Corrections Policy

Report a problem with this story · Copyright & takedown